A Phase 2a Single-Arm, Open-Label, Multicenter Exploratory Study to Assess the Effects of Sotatercept (ACE-011) for the Treatment of Pulmonary Arterial Hypertension
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs Sotatercept (Primary) ; Antihypertensives
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms SPECTRA
- Sponsors Acceleron Pharma
- 20 Mar 2019 Planned initiation date changed from 1 Feb 2019 to 25 Mar 2019.
- 27 Feb 2019 According to an Acceleron Pharma media release, preliminary results expected in 2020.
- 27 Feb 2019 Status changed from not yet recruiting to recruiting, according to an Acceleron Pharma media release.